6 results
This study involves research and the objective of this study is to evaluate how much and how fast TMC278 is absorbed into the body after administration as these concept pediatric formulations compared to when administered as the 25 mg TMC278 tablet…
- To evaluate the effect of steady-state TMC278 25 mg q.d. on the steady-state pharmacokinetics of R- and S-methadone.- To evaluate the potential effect of TMC278 on the pharmacodynamic effects of methadone therapy; - To evaluate the steady state…
The primary objective of the trial is to demonstrate non-inferiority of treatment with TMC278 when administered as 75 mg q.d. compared to the control group (EFV) in regard to the proportion of virologic responders (plasma viral load < 50 HIV-…
To study pharmacokinetics of intravenously and intraperitoneally administered bevacizumab in patients with malignant ascites for whom there is no systemic anti-tumour treatment available.
To identify biological effects of bevacizumab therapy and to visualize distribution kinetics of 111In-bevacizumab with gamma-camera imaging.
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…